Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between ranibizumab and bevacizumab

San Ni Chen, Iebin Lian, Ya Chi Hwang, Yi Hsing Chen, Yao Chung Chang, Kun Hsien Lee, Chih Chun Chuang, Wei Chi Wu

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: To compare the effect and the treatment outcomes of bevacizumab and ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP). Methods: This was a bicentered retrospective case series performed at institutional referral centers. Seventy-two eyes of 37 patients who had intravitreal injections of either bevacizumab or ranibizumab as the primary treatment for Type 1 ROP were included. Outcomes' measures included regression and recurrence of ROP, the surgical complications, and refractive errors at a corrected age of 1 year. Results: All but one eye in the bevacizumab group had retinal neovascularization and plus disease regression after anti-vascular endothelium growth factor treatment. Neither recurrence of ROP nor major ocular complications, including cataract, retinal detachment, and endophthalmitis occurred in any of the treated eyes. There were no significant differences in mean refractive errors between the patients treated with intravitreal injections of bevacizumab or ranibizumab at the corrected age of 1 year. A significantly higher chance of high myopia was noted in the bevacizumab group (P 0.03). Conclusion: Both bevacizumab and ranibizumab showed similar efficacy in the regression of ROP with minor mean refractive errors at 1 year of corrected age. However, high myopia was more prevalent in the bevacizumab-treated eyes.

Original languageEnglish
Pages (from-to)667-674
Number of pages8
JournalRetina
Volume35
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Retinopathy of Prematurity
Vascular Endothelial Growth Factor A
Refractive Errors
Intravitreal Injections
Myopia
Therapeutics
Retinal Neovascularization
Recurrence
Medical Errors
Endophthalmitis
Vascular Endothelium
Retinal Detachment
Ranibizumab
Bevacizumab
Cataract
Intercellular Signaling Peptides and Proteins
Referral and Consultation
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Chen, San Ni ; Lian, Iebin ; Hwang, Ya Chi ; Chen, Yi Hsing ; Chang, Yao Chung ; Lee, Kun Hsien ; Chuang, Chih Chun ; Wu, Wei Chi. / Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity : Comparison between ranibizumab and bevacizumab. In: Retina. 2015 ; Vol. 35, No. 4. pp. 667-674.
@article{7df0d8f6a7b94650a5dbf0122f4f97a0,
title = "Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between ranibizumab and bevacizumab",
abstract = "Purpose: To compare the effect and the treatment outcomes of bevacizumab and ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP). Methods: This was a bicentered retrospective case series performed at institutional referral centers. Seventy-two eyes of 37 patients who had intravitreal injections of either bevacizumab or ranibizumab as the primary treatment for Type 1 ROP were included. Outcomes' measures included regression and recurrence of ROP, the surgical complications, and refractive errors at a corrected age of 1 year. Results: All but one eye in the bevacizumab group had retinal neovascularization and plus disease regression after anti-vascular endothelium growth factor treatment. Neither recurrence of ROP nor major ocular complications, including cataract, retinal detachment, and endophthalmitis occurred in any of the treated eyes. There were no significant differences in mean refractive errors between the patients treated with intravitreal injections of bevacizumab or ranibizumab at the corrected age of 1 year. A significantly higher chance of high myopia was noted in the bevacizumab group (P 0.03). Conclusion: Both bevacizumab and ranibizumab showed similar efficacy in the regression of ROP with minor mean refractive errors at 1 year of corrected age. However, high myopia was more prevalent in the bevacizumab-treated eyes.",
author = "Chen, {San Ni} and Iebin Lian and Hwang, {Ya Chi} and Chen, {Yi Hsing} and Chang, {Yao Chung} and Lee, {Kun Hsien} and Chuang, {Chih Chun} and Wu, {Wei Chi}",
year = "2015",
month = "4",
day = "1",
doi = "10.1097/IAE.0000000000000380",
language = "English",
volume = "35",
pages = "667--674",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity : Comparison between ranibizumab and bevacizumab. / Chen, San Ni; Lian, Iebin; Hwang, Ya Chi; Chen, Yi Hsing; Chang, Yao Chung; Lee, Kun Hsien; Chuang, Chih Chun; Wu, Wei Chi.

In: Retina, Vol. 35, No. 4, 01.04.2015, p. 667-674.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity

T2 - Comparison between ranibizumab and bevacizumab

AU - Chen, San Ni

AU - Lian, Iebin

AU - Hwang, Ya Chi

AU - Chen, Yi Hsing

AU - Chang, Yao Chung

AU - Lee, Kun Hsien

AU - Chuang, Chih Chun

AU - Wu, Wei Chi

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Purpose: To compare the effect and the treatment outcomes of bevacizumab and ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP). Methods: This was a bicentered retrospective case series performed at institutional referral centers. Seventy-two eyes of 37 patients who had intravitreal injections of either bevacizumab or ranibizumab as the primary treatment for Type 1 ROP were included. Outcomes' measures included regression and recurrence of ROP, the surgical complications, and refractive errors at a corrected age of 1 year. Results: All but one eye in the bevacizumab group had retinal neovascularization and plus disease regression after anti-vascular endothelium growth factor treatment. Neither recurrence of ROP nor major ocular complications, including cataract, retinal detachment, and endophthalmitis occurred in any of the treated eyes. There were no significant differences in mean refractive errors between the patients treated with intravitreal injections of bevacizumab or ranibizumab at the corrected age of 1 year. A significantly higher chance of high myopia was noted in the bevacizumab group (P 0.03). Conclusion: Both bevacizumab and ranibizumab showed similar efficacy in the regression of ROP with minor mean refractive errors at 1 year of corrected age. However, high myopia was more prevalent in the bevacizumab-treated eyes.

AB - Purpose: To compare the effect and the treatment outcomes of bevacizumab and ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP). Methods: This was a bicentered retrospective case series performed at institutional referral centers. Seventy-two eyes of 37 patients who had intravitreal injections of either bevacizumab or ranibizumab as the primary treatment for Type 1 ROP were included. Outcomes' measures included regression and recurrence of ROP, the surgical complications, and refractive errors at a corrected age of 1 year. Results: All but one eye in the bevacizumab group had retinal neovascularization and plus disease regression after anti-vascular endothelium growth factor treatment. Neither recurrence of ROP nor major ocular complications, including cataract, retinal detachment, and endophthalmitis occurred in any of the treated eyes. There were no significant differences in mean refractive errors between the patients treated with intravitreal injections of bevacizumab or ranibizumab at the corrected age of 1 year. A significantly higher chance of high myopia was noted in the bevacizumab group (P 0.03). Conclusion: Both bevacizumab and ranibizumab showed similar efficacy in the regression of ROP with minor mean refractive errors at 1 year of corrected age. However, high myopia was more prevalent in the bevacizumab-treated eyes.

UR - http://www.scopus.com/inward/record.url?scp=84926174009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926174009&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000380

DO - 10.1097/IAE.0000000000000380

M3 - Article

C2 - 25462435

AN - SCOPUS:84926174009

VL - 35

SP - 667

EP - 674

JO - Retina

JF - Retina

SN - 0275-004X

IS - 4

ER -